North Star Asset Management Inc. Purchases 5,160 Shares of Illumina, Inc. (NASDAQ:ILMN)

North Star Asset Management Inc. lifted its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 6.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 85,604 shares of the life sciences company's stock after acquiring an additional 5,160 shares during the quarter. North Star Asset Management Inc. owned 0.05% of Illumina worth $11,439,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in ILMN. Golden State Wealth Management LLC purchased a new stake in Illumina during the fourth quarter valued at $32,000. Fourth Dimension Wealth LLC bought a new stake in Illumina during the 4th quarter valued at $40,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in Illumina during the 4th quarter worth about $45,000. Assetmark Inc. grew its holdings in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after acquiring an additional 296 shares in the last quarter. Finally, Lee Danner & Bass Inc. bought a new position in Illumina during the 4th quarter worth about $48,000. 89.42% of the stock is currently owned by institutional investors.

Insider Transactions at Illumina

In related news, CFO Ankur Dhingra bought 6,100 shares of the business's stock in a transaction on Monday, May 12th. The shares were purchased at an average cost of $81.21 per share, with a total value of $495,381.00. Following the acquisition, the chief financial officer now owns 24,906 shares of the company's stock, valued at $2,022,616.26. This represents a 32.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. HSBC lowered shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target for the company. in a research report on Friday, February 28th. JPMorgan Chase & Co. decreased their price objective on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Citigroup decreased their price objective on shares of Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. Hsbc Global Res lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Finally, Morgan Stanley decreased their price objective on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating for the company in a research report on Monday, May 12th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $128.15.

Illumina Stock Performance

Shares of NASDAQ:ILMN traded up $2.12 during trading on Tuesday, hitting $82.49. 2,197,475 shares of the stock were exchanged, compared to its average volume of 2,325,969. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company has a market capitalization of $13.06 billion, a price-to-earnings ratio of -10.74, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35. The company's fifty day simple moving average is $78.04 and its 200-day simple moving average is $107.89. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.01. The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.03 billion. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The company's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.98 earnings per share. Sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.